Prostate Cancer Update

Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics:

• Introduction: Welcome GU Oncology Fellows! (0:00)
• Prostate Cancer — Dr Aggarwal (12:48)
• Urothelial Bladder Cancer — Dr Galsky (45:01)
• Renal Cell Carcinoma — Dr Zhang (1:10:52)

CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:

• Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)
• Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00)
• Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40)

CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:

• Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)
• Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01)
• Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

• Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00)
• Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is ineligible for cisplatin because of poor renal function undergoes cystectomy (10:12)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

• Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00)
• Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (11:20)

CME information and select publications

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42)
• Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23)
• Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01)
• Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22)
• Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37)

CME information and select publications

Featuring an interview with Dr Rana R McKay, including the following topics:

• Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
• Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
• Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
• Takeaways from the Phase III EMBARK study (19:36)
• Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
• Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:

• Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
• Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
• Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
• Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
• Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:

• Introduction: Life After Radical Cystectomy (0:00)
• Muscle-Invasive Bladder Cancer — Prof Powles (9:15)
• Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:

• Introduction (0:00)
• Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)
• Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)

CME information and select publications